GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Vectus Biosystems Ltd (ASX:VBS) » Definitions » ROE % Adjusted to Book Value

Vectus Biosystems (ASX:VBS) ROE % Adjusted to Book Value : -11.99% (As of Dec. 2023)


View and export this data going back to 2016. Start your Free Trial

What is Vectus Biosystems ROE % Adjusted to Book Value?

Vectus Biosystems's ROE % for the quarter that ended in Dec. 2023 was -79.95%. Vectus Biosystems's PB Ratio for the quarter that ended in Dec. 2023 was 6.67. Vectus Biosystems's ROE % Adjusted to Book Value for the quarter that ended in Dec. 2023 was -11.99%.


Vectus Biosystems ROE % Adjusted to Book Value Historical Data

The historical data trend for Vectus Biosystems's ROE % Adjusted to Book Value can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Vectus Biosystems ROE % Adjusted to Book Value Chart

Vectus Biosystems Annual Data
Trend Jun16 Jun17 Jun18 Jun19 Jun20 Jun21 Jun22 Jun23
ROE % Adjusted to Book Value
Get a 7-Day Free Trial - - - - -

Vectus Biosystems Semi-Annual Data
Jun16 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23
ROE % Adjusted to Book Value Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - -82.13 -9.40 -11.99

Competitive Comparison of Vectus Biosystems's ROE % Adjusted to Book Value

For the Biotechnology subindustry, Vectus Biosystems's ROE % Adjusted to Book Value, along with its competitors' market caps and ROE % Adjusted to Book Value data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Vectus Biosystems's ROE % Adjusted to Book Value Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Vectus Biosystems's ROE % Adjusted to Book Value distribution charts can be found below:

* The bar in red indicates where Vectus Biosystems's ROE % Adjusted to Book Value falls into.



Vectus Biosystems ROE % Adjusted to Book Value Calculation

Vectus Biosystems's ROE % Adjusted to Book Value for the fiscal year that ended in Jun. 2023 is calculated as

ROE % Adjusted to Book Value=ROE % / PB Ratio
=0.00% / 6.67
=0.00%

Vectus Biosystems's ROE % Adjusted to Book Value for the quarter that ended in Dec. 2023 is calculated as

ROE % Adjusted to Book Value=ROE % / PB Ratio
=-79.95% / 6.67
=-11.99%

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Vectus Biosystems ROE % Adjusted to Book Value Related Terms

Thank you for viewing the detailed overview of Vectus Biosystems's ROE % Adjusted to Book Value provided by GuruFocus.com. Please click on the following links to see related term pages.


Vectus Biosystems Business Description

Traded in Other Exchanges
N/A
Address
3-11 Primrose Avenue, Rosebery, Sydney, NSW, AUS, 2018
Vectus Biosystems Ltd is an emerging biotechnology company based in Sydney, Australia. The company is in the process of developing a treatment for fibrosis and high blood pressure, which includes heart, kidney, and liver diseases. The company has also developed a technology aimed at improving the speed and accuracy of measuring the amount of DNA and RNA in samples tested in laboratories.

Vectus Biosystems Headlines

No Headlines